Praxis Precision Medicines

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on translating insights from genetic epilepsies into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. Their mission is to deliver life-altering treatments faster and more effectively to patients with CNS disorders, driven by a purpose to create lasting impact for those in need.

Products & Services

Precision Therapies for CNS Disorders:A portfolio of therapies targeting central nervous system disorders, with four clinical-stage assets and multiple early-stage programs.

Treatments Inspired by Genetics of Epilepsy:Developing treatments based on genetic insights into epilepsy, enabled by two platforms.

Specialties

Genetic Epilepsies Central Nervous System (CNS) Disorders Neuronal Excitation-Inhibition Imbalance Translational Tools Patient-Guided Development Human Genetics-Based Therapeutic Targets

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 575000000 MR: - FA: 575 million FAN: 575000000	D: 2026-01-06 FD: 2026-01-06	9 investors
2	RT: Public Offering T: - FT: Public Offering	A: 525000000 MR: - FA: approximately $525 million FAN: 525000000	D: 2025-10-16 FD: 2025-10-16	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: approximately $200 million FAN: 200000000	D: 2024-03-28 FD: 2024-03-28	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150.0 million FAN: 150000000	D: 2024-01-11 FD: 2024-01-11	3 investors
5	RT: Public Offering T: - FT: Public Offering	A: 63300000 MR: - FA: $63.3 million FAN: 63300000	D: 2023-06-22 FD: 2023-06-22	-
6	RT: Public Offering T: - FT: Public Offering	A: 59100000 MR: - FA: $59.1 million FAN: 59100000	D: 2023-06-15 FD: 2023-06-15	2 investors

Public Offering Latest

2026-01-06

$575.0M

9 investors (Pro only)

Public Offering 2025-10-16

$525.0M

Public Offering 2024-03-28

$200.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sam Berkovic

Laureate Professor in the Department of Medicine, University of Melbourne and Director of the Epilepsy Research Centre at Austin Health, Australia

I

Ingrid Scheffer

I

Ivan Soltesz

James R. Doty Professor of Neurosurgery and Neurosciences

J

James R. Doty

H

Holger Lerche

Professor of Neurology and Clinical Director

A

Anna Greka

Professor of Medicine

View 24 more team members with Pro

Unlock Full Team Directory

Recent News